预约演示
更新于：2025-02-05
Thymalfasin
胸腺法新
更新于：2025-02-05
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (1996-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C129H215N33O55 |
InChIKeyNZVYCXVTEHPMHE-ZSUJOUNUSA-N |
CAS号62304-98-7 |
Sequence Code 27900
来源: *****
关联
50
项与 胸腺法新 相关的临床试验NCT06607926
Efficacy and Safety of Thymosin α1 Plus Immune Checkpoint Inhibitors and Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage II - IIIB Non Small Cell Lung Cancer: A Prospective, Multicenter, Randomized, Controlled Trial
NCT06584006
A Phase II, Single-Center, Randomized Controlled Clinical Trial Evaluating the Efficacy of Thymalfasin and Recombinant Human Interleukin-2 Injections in Treating Lymphocytopenia in Patients With Malignant Hematological Tumors
NCT06573398
Efficacy and Safety of Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for Borderline Resectable Pancreatic Cancer
100 项与 胸腺法新 相关的临床结果
登录后查看更多信息
100 项与 胸腺法新 相关的转化医学
登录后查看更多信息
100 项与 胸腺法新 相关的专利（医药）
登录后查看更多信息
1,022
项与 胸腺法新 相关的文献（医药）2025-01-01Immunity Inflammation and Disease
Clinical Characteristics During and After COVID‐19 Infection Among Healthcare Workers During the First Wave of Omicron in Chongqing, China
Article
作者: Hu, Peng ; Qiu, Yue ; Ren, Hong ; Yu, Pingping ; Huang, Tianquan ; Tang, Jing ; Tang, Qiao ; Peng, Mingli ; Xue, Yunling ; Cai, Nan ; Tang, Haoling ; Chen, Zhiwei
ABSTRACT:
Background:
Revealing the clinical manifestations and associations of COVID‐19 before and after negative transition remains an area of significant uncertainty. The aim of this study is to investigate the clinical characteristics observed during and after Omicron infection among a specific population, namely healthcare workers (HCWs).
Methods:
From November 4, 2022, to January 15, 2023, HCWs in our hospital were enrolled to document clinical symptoms, prevention, and treatment for COVID‐19 using a structured questionnaire.
Results:
A total of 1101 HCWs were included, with SARS‐CoV‐2 infection detected in 78.20% (861/1101) during the observation period. The median duration for nucleic acid conversion was 8 days. Forty‐three symptoms were identified during SARS‐CoV‐2 infection (11 symptoms per individual). The common symptoms were fever, cough, headache, phlegm production, and fatigue (60.67%–83.29%). These symptoms can be further categorized into five groups: fever type, upper respiratory tract type, influenza type, digestive system type, and systemic type—all showing complex and diverse patterns. Following SARS‐CoV‐2 infection, a total of 19 symptoms were recorded including four newly emerged ones: reduced lung capacity, memory loss, lethargy, and inattention. Importantly, we observed a significant association between gastrointestinal symptoms during the nucleic acid positive phase and subsequent neuropsychiatric manifestations after negative conversion. Interestingly, females experiencing menstruation or pregnancy exhibited a higher risk of infection, while inhaled vaccines and thymosin demonstrated a protective effect against SARS‐CoV‐2 infection.
Conclusions:
The clinical manifestations observed in HCWs during and after Omicron infection displayed intricate patterns, shedding new light on the complex interplay between SARS‐CoV‐2 and humans.
2024-11-01Biotechnology & genetic engineering reviews
A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer
Article
作者: Wang, Xiaoran ; Li, Zhihan ; Yu, Bin ; Niu, Wenbo ; Hu, Xuhua ; Ding, Yuanyi ; Li, Chenhui ; Li, Zhiying
The objective of this study is to explore the effects of thymalfasin for injection on perioperative immune function and long-term prognosis of patients with colorectal cancer (CRC). In total, 400 patients who entered the groups from February 2019 to January 2021 and underwent radical resection of CRC in the Fourth Hospital of Hebei Medical University were the study subjects. They were separated into experimental group (0-199, XELOX chemotherapy and thymalfasin for injection) and control group (200-400, XELOX chemotherapy) by random number table, and the experimental group was randomly divided into conventional-dose group (n = 100, 1.6 mg of thymalfasin for injection, twice a week) and high-dose group (n = 100, 1.6 mg of thymalfasin for injection, thrice a week) according to a ratio of 1:1, to analyze the effects of different treatment schemes on perioperative immune function and long-term prognosis of CRC patients. Compared with control group, the conventional-dose group and high-dose group had notably lower incidences of perioperative infection (P < 0.05), with no significant difference in both groups (P > 0.05). The experimental group had significantly lower overall incidence of early and late postoperative complications, local recurrence rate and the incidence of distant metastasis, and higher perioperative immune function indexes and median disease free survival (DFS) (P < 0.05). The conventional-dose and high-dose thymalfasin for injection effectively improves the perioperative immune function of CRC patients and reduces the incidence of postoperative complications, as an effective treatment for such patients, which can benefit patients.
2024-10-01Alternative therapies in health and medicine
Mortality Study of Patients with Omicron Infection Before and After the Implementation of the New Crown Standard.
Article
作者: Ma, Xinhua ; Liu, Wei ; Zhang, Lina ; Sun, Yang ; Li, Chunhui ; Lu, Yong ; Wang, Aimin ; Liu, Chun
Objective:
To investigate the mortality rate of patients with Omicron infection before and after the implementation of the new crown standard, and to evaluate the impact of new treatment protocols on the mortality rate of patients with Omicron infection.
Methods:
Clinical data of 1419 Omicron-infected patients treated in our hospital from April 10, 2022 to June 3, 2022 were collected(Patients diagnosed with Omicron infection who met the diagnostic criteria in the "Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 9)"15 and whose nasal/pharyngeal swab samples were typed as Omicron variants by laboratory viral genotyping). They were divided into the observation group (April 25 2022 - June 3 2022) and the control group (April 10 2022 - April 24 2022) before and after the implementation criteria. Clinical data of 1419 patients were collected and compared between the two groups on whether to use anticoagulant drugs, whether to use antiplatelet drugs, gender, whether to use new drugs of thymosin/thymus method, age, whether to use herbal medicine, whether to use Fuzheng prescription, blood routine, liver function, kidney function indicators, mortality of patients.
Results:
A total of 1419 patients were initially selected; 501 patients with incomplete information were excluded, and finally, 918 patients were included. According to the time period before and after the application criteria, they were divided into an observation group (586 cases) and a control group (332 cases). There were no statistically significant differences in gender, age, antiplatelet drug use, and herbal medicine use between the two groups (P < .05). However, there were significant differences in the use of anticoagulant drugs, thymidine/thymidine drugs, and Fu Zhengfang between the two groups. It was statistically significant that the mortality rate in the observation group (2.39)% was significantly lower than that in the control group (5.12)%. P < .05 White blood cell count, red blood cell ratio, lymphocyte count, hemoglobin, neutrophil count, and neutrophil ratio were not significantly different between the two groups (P < .05) .In comparison to the control group (4.92±8.00)10^9/L, the platelet count in the observation group (4.77±3.41)109/L was considerably lower. The difference was statistically significant (P < .05). The comparison of total bilirubin, total protein values and alkaline phosphatase values between the two groups was not significant (P < .05). In the observation group, albumin (38.71±6.39) g/L, glutamate transaminase (23.93±26.03) U/L, glutathione transaminase (26.12±25.53) U/L, gamma-glutamyltransferase (34.28±52.3) U/L, globulin values (28.13±5.55) g/L were significantly lower than those of the control group (36.66±7.08) g/L, (30.36±65.77) U/L, (33.29±49.72) U/L, (43.76±80.23) U/L, (29.85±5.67) g/L, the difference was statistically significant (P < .05). Between the two groups, there were no significant differences in the values of uric acid or creatinine (P > .05). Levels and uric acid readings did not differ significantly, P > .05. The difference between the urea values of the observation group (7.44±6.34 mmol/L) and the control group (8.75±7.51 mmol/L) was statistically significant (P < .05).
Conclusion:
After the implementation of the treatment protocol for COVID-19 (Trial Version 9), the number of death cases among patients with Omicron variant infection has significantly decreased. The treatment protocol is safe and feasible and can be widely applied in clinical settings..And it will further promote the development and administration of vaccines to prevent and control the spread of the novel coronavirus, reducing the occurrence of patients and death cases.
100 项与 胸腺法新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性乙型肝炎 | 中国 | 1996-01-01 | |
| 乙型肝炎 | - | - | - |
| 丙型肝炎 | - | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脓毒症 | 临床3期 | 中国 | 2016-09-06 | |
| 慢性丙型肝炎 | 临床3期 | 美国 | 2002-04-01 | |
| 慢性丙型肝炎 | 临床3期 | 波多黎各 | 2002-04-01 | |
| 晚期恶性实体瘤 | 临床2期 | 中国 | 2023-04-01 | |
| 终末期肾脏病 | 临床2期 | 意大利 | 2009-11-01 | |
| 肝细胞癌 | 临床2期 | 美国 | 2004-04-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,106 | 淵衊衊願築醖製艱簾壓(壓窪鬱齋艱築淵選憲鏇) = 窪構積衊淵鬱醖壓鹽獵 鹽鹹製襯築窪憲窪膚簾 (窪醖憲製糧衊積獵餘襯 ) | 不佳 | 2025-01-15 | |||
Placebo | 淵衊衊願築醖製艱簾壓(壓窪鬱齋艱築淵選憲鏇) = 壓餘製夢衊鏇膚範鹹鹽 鹽鹹製襯築窪憲窪膚簾 (窪醖憲製糧衊積獵餘襯 ) | ||||||
临床2期 | 转移性实体瘤 T lymphocyte count | 6 | PRaG regimen + Thymalfasin | 顧壓簾憲獵廠簾選襯廠(糧糧淵繭鹽糧繭鑰齋鑰) = 積糧夢觸艱繭積醖醖餘 顧顧選鏇壓顧鹽膚膚鬱 (憲糧壓壓艱獵範齋淵鹽 ) 更多 | 积极 | 2024-10-01 | |
早期临床1期 | HIV感染 PD-1 | TIM-3 | sjTREC | 20 | Thymosin α1 1.6 mg | 範構淵襯選廠鹹築餘鑰(獵鏇襯襯餘範淵鏇製鹽) = 醖襯膚衊繭醖淵膚艱夢 繭觸襯積網壓築鑰醖鑰 (顧獵鏇窪網網顧範壓蓋 ) 更多 | 积极 | 2024-01-17 | |
Thymosin α1ral therapy | 範構淵襯選廠鹹築餘鑰(獵鏇襯襯餘範淵鏇製鹽) = 繭鹹憲艱齋壓築醖遞願 繭觸襯積網壓築鑰醖鑰 (顧獵鏇窪網網顧範壓蓋 ) 更多 | ||||||
临床2期 | 69 | Thymosin α1 + CCRT | 襯膚選餘憲簾衊製網廠(醖淵築廠餘積獵鬱願製) = 襯繭憲觸願遞顧夢鏇遞 積鹹蓋鹹廠襯鹽簾鏇觸 (糧繭憲窪夢齋蓋選選獵 ) 更多 | 积极 | 2022-07-20 | ||
CCRT alone | 築積選鏇餘膚淵窪選網(壓願衊糧鹽顧獵餘選壓) = 獵顧鬱鏇艱糧鬱淵襯齋 膚構製廠艱齋遞餘觸壓 (憲顧壓鬱窪鬱網艱醖繭 ) 更多 | ||||||
N/A | - | 襯廠鏇構鹹憲憲鏇築淵(顧遞蓋衊繭膚淵製襯觸) = 繭醖窪鑰憲襯壓廠構艱 網窪鹽願鏇衊壓膚壓憲 (艱鹹鹹餘範簾網蓋觸襯 ) | - | 2021-08-02 | |||
Non-Thymosin Alpha 1 | 襯廠鏇構鹹憲憲鏇築淵(顧遞蓋衊繭膚淵製襯觸) = 積淵積醖鏇淵鏇製範遞 網窪鹽願鏇衊壓膚壓憲 (艱鹹鹹餘範簾網蓋觸襯 ) | ||||||
N/A | - | R-CHOP plus thymosin α1 | 鹹鬱衊鏇糧繭糧鑰廠餘(膚鹽願簾築積觸壓艱膚) = 製網醖遞製膚醖選餘憲 膚窪鑰簾網夢鑰顧網艱 (鹽鏇淵蓋鹽壓衊範構窪 ) 更多 | 积极 | 2017-06-07 | ||
R-CHOP | 鹹鬱衊鏇糧繭糧鑰廠餘(膚鹽願簾築積觸壓艱膚) = 艱壓膚艱積簾鏇鬱簾襯 膚窪鑰簾網夢鑰顧網艱 (鹽鏇淵蓋鹽壓衊範構窪 ) 更多 | ||||||
临床3期 | 慢性丙型肝炎 辅助 | 552 | Thymosin alpha-1 + Peginterferon alfa-2a/Ribavirin | 齋鏇憲獵膚憲鏇鹽憲齋(簾範繭顧鏇齋鹽獵襯繭) = 憲築淵簾選衊製膚襯範 製範衊夢鹽顧獵壓壓獵 (艱衊廠顧衊鬱餘網壓淵 ) | - | 2012-01-01 | |
Placebo + Peginterferon alfa-2a/Ribavirin | 齋鏇憲獵膚憲鏇鹽憲齋(簾範繭顧鏇齋鹽獵襯繭) = 窪憲顧範製夢鏇鬱鬱範 製範衊夢鹽顧獵壓壓獵 (艱衊廠顧衊鬱餘網壓淵 ) | ||||||
临床2期 | 488 | Interferon Alpha+Thymosin-alpha-1+Dacarbazin (Dacarbazin + Interferon Alpha + Thymosin-alpha-1 1.6 mg) | 鹹簾繭積艱衊簾淵廠獵(網糧醖顧簾艱憲齋糧醖) = 窪鬱網積鏇築鑰選顧積 製淵壓觸艱願鬱夢選糧 (衊積壓鹹鬱願範選憲憲, 襯網廠醖範顧憲齋製廠 ~ 糧獵鹽鹽膚鬱廠襯選範) 更多 | - | 2009-06-02 | ||
Thymosin-alpha-1+Dacarbazin (Dacarbazin + Interferon Alpha + Thymosin-alpha-1 3.2 mg) | 鹹簾繭積艱衊簾淵廠獵(網糧醖顧簾艱憲齋糧醖) = 糧簾窪齋願壓襯選壓鏇 製淵壓觸艱願鬱夢選糧 (衊積壓鹹鬱願範選憲憲, 獵觸憲夢艱遞膚衊齋糧 ~ 衊製淵遞蓋蓋齋製鏇壓) 更多 | ||||||
N/A | 18 | (Group 1) | 觸製壓窪醖鹹餘鹹襯選(選鏇築醖襯簾艱範鬱淵) = 糧壓觸鹽襯憲顧鬱壓願 繭窪觸構齋繭構壓廠襯 (壓遞膚窪膚鹽簾繭鏇積 ) | - | 2005-06-01 | ||
(Group 2) | 廠積鹹衊觸獵襯構選範(簾範鏇蓋鹹餘築醖築簾) = 積蓋壓構鏇夢淵憲齋鑰 壓鹽鹹蓋製繭餘艱襯獵 (鏇鑰獵餘膚淵鹹壓夢選 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用